| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00213-005-0081-9 |
| P698 | PubMed publication ID | 16001110 |
| P2093 | author name string | Diane M Ignar | |
| Claire Rourke | |||
| Declan N C Jones | |||
| Mikhail Kalinichev | |||
| Christy S Britt | |||
| Mary K Grizzle | |||
| Alex J Daniels | |||
| P2860 | cites work | Antipsychotic-induced weight gain: a comprehensive research synthesis | Q28146256 |
| The role of atypical antipsychotics in bipolar depression and anxiety disorders | Q28236713 | ||
| Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health | Q28288766 | ||
| A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat | Q28368216 | ||
| Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia | Q31842937 | ||
| The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia | Q33693516 | ||
| Weight gain: side effect of atypical neuroleptics? | Q33707031 | ||
| Body weight gain induced by antipsychotic drugs: mechanisms and management | Q33708467 | ||
| Novel antipsychotics: comparison of weight gain liabilities. | Q33867682 | ||
| The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor | Q33959664 | ||
| The clinical implications of weight gain in schizophrenia. | Q34247431 | ||
| Dosing the antipsychotic medication olanzapine | Q34436327 | ||
| Antipsychotics: impact on prolactin levels | Q34974785 | ||
| A review of the effect of atypical antipsychotics on weight | Q35035150 | ||
| The effects of atypical antipsychotics on serum prolactin levels | Q35065701 | ||
| Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics | Q35618430 | ||
| Hyperprolactinaemia and antipsychotic therapy in schizophrenia | Q35684486 | ||
| Antipsychotic drugs and obesity: is prolactin involved? | Q40669926 | ||
| Pharmacokinetics and tissue distribution of olanzapine in rats | Q41743714 | ||
| Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial | Q42550364 | ||
| Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. | Q43541375 | ||
| Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone | Q43622360 | ||
| Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan | Q43666300 | ||
| Novel antipsychotics and severe hyperlipidemia | Q43689715 | ||
| Association of olanzapine-induced weight gain with an increase in body fat. | Q43752224 | ||
| Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods | Q43780546 | ||
| Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine | Q44013107 | ||
| The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved? | Q44054578 | ||
| Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. | Q44167467 | ||
| The effects of excitotoxic hippocampal lesions in rats on risperidone- and olanzapine-induced locomotor suppression | Q44237551 | ||
| Characterization of olanzapine-induced weight gain in rats | Q44263522 | ||
| Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials | Q44428863 | ||
| Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human | Q44448583 | ||
| Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study | Q44452834 | ||
| Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder | Q44513113 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia | Q44649979 | ||
| NMDA receptor antagonists reduce restraint-induced release of prolactin in male rats. | Q44837033 | ||
| An animal model of antipsychotic-induced weight gain | Q44890737 | ||
| Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. | Q44983975 | ||
| Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. | Q45035640 | ||
| Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. | Q46465365 | ||
| Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment | Q47247035 | ||
| Olanzapine increases weight and serum triglyceride levels. | Q47252169 | ||
| 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. | Q47863120 | ||
| Effects of housing on male and female rats: crowding stresses male but calm females. | Q51034168 | ||
| Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. | Q51552711 | ||
| Physiological evidence for the existence of prolactin releasing factor: stress-induced prolactin secretion is not linked to dopaminergic receptors. | Q51872161 | ||
| Olanzapine-induced glucose dysregulation. | Q51975179 | ||
| Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? | Q52531799 | ||
| Social influences on the amount of food eaten by Norway rats. | Q52890777 | ||
| Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. | Q53360074 | ||
| Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug, sulpiride. | Q54120441 | ||
| Predicting medication noncompliance after hospital discharge among patients with schizophrenia | Q73401303 | ||
| Rat sex and strain differences in responses to stress | Q74292110 | ||
| The RXR agonist LG100268 causes hepatomegaly, improves glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancreatic beta-cell dysfunction | Q77762865 | ||
| Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs | Q77882065 | ||
| Diabetic ketoacidosis with olanzapine treatment | Q77892219 | ||
| Hyperglycemia associated with olanzapine | Q77915802 | ||
| New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment | Q78235395 | ||
| P433 | issue | 2 | |
| P921 | main subject | weight gain | Q3403879 |
| P304 | page(s) | 220-231 | |
| P577 | publication date | 2005-10-19 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats | |
| P478 | volume | 182 |
| Q31010040 | A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK population |
| Q47371161 | A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats |
| Q46070377 | Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats |
| Q46128379 | Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects |
| Q51765278 | Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up. |
| Q38850666 | Atypical antipsychotics and effects on feeding: from mice to men. |
| Q51185707 | Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects. |
| Q36383322 | Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. |
| Q45942751 | Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats. |
| Q27012948 | Effect of atypical antipsychotics on fetal growth: is the placenta involved? |
| Q42921304 | Effectiveness and Tolerability of Aripiprazole in Children and Adolescents with Tourette's Disorder: A Pilot Study in China |
| Q34628396 | Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain |
| Q47316994 | Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. |
| Q31023868 | Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data |
| Q37299210 | Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review |
| Q48254506 | GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats |
| Q47559375 | Home alone: a systematic review and meta-analysis on the effects of individual housing on body weight, food intake and visceral fat mass in rodents |
| Q46217077 | Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. |
| Q46726982 | Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats |
| Q34506022 | Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment |
| Q38150595 | Modelling olanzapine-induced weight gain in rats |
| Q47305725 | No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs |
| Q47847071 | Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects. |
| Q47359953 | Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. |
| Q43290436 | Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. |
| Q64071148 | One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects |
| Q37165503 | Pharmacological management of atypical antipsychotic-induced weight gain. |
| Q90294280 | Preclinical and Clinical Sex Differences in Antipsychotic-Induced Metabolic Disturbances: A Narrative Review of Adiposity and Glucose Metabolism |
| Q28569990 | The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats |
| Q34214660 | Translating potential biomarker candidates for schizophrenia and depression to animal models of psychiatric disorders |
| Q36230583 | Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies |
| Q46798743 | Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats |
Search more.